In Vitro Assessment of Antileishmanial Activity of Natamycin and Nystatin
AUTOR(ES)
Sidana, Arushdeep, Negi, Ajeet Kumar, Farooq, Umar
FONTE
Braz. arch. biol. technol.
DATA DE PUBLICAÇÃO
02/05/2017
RESUMO
ABSTRACT The present study was aimed to evaluate the in vitro antileishmanial activity of four different concentrations of natamycin and nystatin by using MTT 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide reduction assay. In vitro antileishmanial activity revealed that the IC50 of natamycin (80.49 μg/ml) and nystatin (105.7 μg/ml) was less than that of sodium stibogluconate (127.9 μg/ml), and more than amphotericin B (18.91 μg/ml).
Documentos Relacionados
- Semiautomated assessment of in vitro activity of potential antileishmanial drugs.
- In Vitro Antileishmanial Activity of Nicotinamide
- In Vitro Activity of Nystatin Compared with Those of Liposomal Nystatin, Amphotericin B, and Fluconazole against Clinical Candida Isolates
- In vitro evaluation of the anti-leishmanial activity and toxicity of PK11195
- Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis.
